Actelion Pharmaceuticals

Special Report: Driving Innovation
June 1, 2007

Direct mail is marketing’s workhorse for a reason. It’s resolute and reliable, even in the face of challenge. According to the Direct Marketing Association’s (DMA) “2006 Response Rate Trends Report,” the medium produces the second highest response rates (behind catalogs) for marketers seeking to solicit direct-order sales or motivate customers to make a charitable contribution. So how does one of the oldest marketing mediums stay effective and relevant despite intense competition? For this special report on production and paper, we asked some of the best and brightest minds in the direct mail business to share their opinions on the trends driving innovation in the

The Road Less Traveled
April 1, 2007

Actelion Pharmaceuticals Ltd. has taken the road less traveled before. It all started when the founders of this independent biopharmaceutical company left Roche to pursue therapeutic applications for several molecules they had discovered. Pharmaceutical giant Roche had opted not to continue the research because of limited market demand. A decade later, Actelion has built a thriving, multinational organization on discovering, developing and marketing drugs for unmet medical needs. Case in point: The company’s flagship drug, Tracleer, treats pulmonary arterial hypertension (PAH), a complex disease historically overlooked by pharmaceutical firms and physicians alike. PAH has been under diagnosed due to a lack of awareness, explains Martin